HC Wainwright Reiterates Buy Rating for Silence Therapeutics (NASDAQ:SLN)

HC Wainwright reiterated their buy rating on shares of Silence Therapeutics (NASDAQ:SLN) in a research report report published on Friday morning,Benzinga reports. They currently have a $75.00 target price on the stock.

SLN has been the subject of several other reports. Morgan Stanley reiterated an “overweight” rating and issued a $49.00 target price on shares of Silence Therapeutics in a research report on Tuesday, October 8th. Chardan Capital restated a “buy” rating and issued a $55.00 price target on shares of Silence Therapeutics in a research report on Thursday. Finally, Jefferies Financial Group started coverage on shares of Silence Therapeutics in a report on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $57.20.

Silence Therapeutics Trading Down 9.2 %

Shares of Silence Therapeutics stock opened at $12.70 on Friday. The firm’s 50 day moving average is $17.98 and its 200 day moving average is $19.12. The firm has a market capitalization of $380.11 million, a PE ratio of -8.09 and a beta of 1.30. Silence Therapeutics has a 1 year low of $8.94 and a 1 year high of $27.72.

Silence Therapeutics (NASDAQ:SLN) last announced its quarterly earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.10). Silence Therapeutics had a negative return on equity of 65.18% and a negative net margin of 342.00%. The company had revenue of $0.76 million for the quarter, compared to analyst estimates of $11.28 million. As a group, research analysts anticipate that Silence Therapeutics will post -1.55 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

Large investors have recently bought and sold shares of the business. Values First Advisors Inc. bought a new stake in Silence Therapeutics in the 3rd quarter valued at about $56,000. Quarry LP purchased a new stake in shares of Silence Therapeutics during the 2nd quarter valued at $114,000. SG Americas Securities LLC raised its stake in shares of Silence Therapeutics by 10.5% during the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock worth $151,000 after purchasing an additional 667 shares during the period. Verition Fund Management LLC purchased a new position in shares of Silence Therapeutics in the 3rd quarter worth about $207,000. Finally, Custom Index Systems LLC bought a new position in Silence Therapeutics during the second quarter valued at about $282,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.